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Background: For the cardiac surgeon and patient the development of sternal wound infection is a serious
post-operative complication associated with increased risk of death and also considerable morbidity.
Methods: Nine publications were identiﬁed using the PubMed online database and search terms
‘gentamicin-containing collagen implant’ plus ‘surgical site infection’, ‘wound infection’ and ‘cardiac
surgery’.
Results: Six out of eight studies demonstrated that prophylactic use of gentamicin-containing collagen
implants (GCCI) signiﬁcantly reduce the wound infection rate following cardiac surgery (via sternotomy)
compared to standard treatment alone. The adjunctive use of GCCI is particularly beneﬁcial in high-risk
subjects e.g. diabetes and obese patients. GCCI signiﬁcantly improve the morbidity associated with SSI
following cardiac surgery by shortening the recovery phase and length of hospital stay; reducing the
need for surgical revision and use of antibiotics. GCCI have been shown to be cost saving across a wide
spectrum of patients. A further study has shown that GCCI may also have a therapeutic role to play in
patients with deep sternal wounds.
Conclusion: This reviewdemonstrates thatwhen used dry prior to insertionGCCI canbe effective in reducing
the rate of SSI following cardiac surgery. GCCI have also been shown to be cost saving as they reduce the
substantial morbidity associated with deep SSI. The adjunctive use of GCCI is particularly beneﬁcial in high-
risk patients. GCCI may also have a role to play in the treatment of deep sternal wound infection.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
For the cardiac surgeon and patient the development of sternal
wound infection is a serious post-operative complication associ-
ated with increased risk of death and also considerable morbidity,
which in turn may substantially increase the length of hospital stay
and associated cost of care. Sternal wound infection has a reported
overall incidence between 0.5% and 6%.1 However, in high-risk
patients the incidence has been estimated at between 12 and 20%
with an associated mortality rate between 14% and 47%.1
Independent risk factors associated with the development of
surgical site infection (SSI) following cardiac surgery have been
established by a number of authors.2e4 In a study published in 2009
of 1359 cardiac surgery patients the presence of diabetes mellitus,
chronic obstructive pulmonary disease (COPD) or a higher body
mass index (BMI) increased the risk of patients developing deep
sternal wound infection.3 The length of time the patients were on
cardiopulmonary bypass was also established as an independent
risk factor for sternal wound infection.3992.
ciates Ltd. Published by Elsevier LtSSI is also an important cause of morbidity for patients under-
going cardiac surgery, which is reﬂected in the increased length of
hospital stay (LOS) and associated costs.5,6 For patients with deep
sternal wound infections the LOS may increase from a mean of 10.7
days in infection-free patients to 35 days in patients with an SSI
(p < 0.001).5 Coello and colleagues estimated that the cost associ-
ated with the increased LOS for coronary artery bypass graft (CABG)
patients who developed an SSI to be in the region of V4400.6 The
mean total cost associated with an SSI (i.e. including surgical revi-
sion, days in ICUetc) followingcardiac surgeryhas beenestimated to
be V14,500 by Friberg and colleagues.7
Another challenge that the cardiac surgeon faces in trying to
prevent SSI is that coagulase-negative staphylococci (CoNS) have
become the most common causative organisms of sternal wound
infections.8 With CoNS infections the onset of SSI may be delayed
and more insidious and may eventually require radical surgical
revision to eradicte the infection.9
The mainstay of SSI prevention in cardiac surgery relies on
aseptic surgery, an optimal wiring technique and the use of anti-
biotic prophylaxis administered systemically peri-operatively.4,10
Long-term administration of systemic antibiotics may in turn lead
to a greater risk of antibiotic resistance.11e14d. All rights reserved.
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resorbable gentamicin-containing collagen implant (GCCI), deliver
high local concentrations of gentamicin with corresponding low
serum levels. This technology therefore offers a means of lowering
the risk of antibiotic resistance by reducing the need for long-term
administration of systemic antibiotics and also may avoid the
toxicity of these regimens.3 The use of collagen as a carrier also has
a positive effect on wound healing.15
The objective of this article is to review the published clinical
data for prophylactic application of resorbable GCCI following
cardiac surgery in order to provide an overview of the efﬁcacy and
safety of GCCI in this indication with particular focus on high-risk
patient groups.
2. Methods
Candidate publications were identiﬁed using the National Institute of Health
PubMed database for articles published between January 1990 and July 2011. Articles
were identiﬁed using the search terms ‘gentamicin-containing collagen implant’
plus ‘surgical site infection’, ‘wound infection’ and ‘cardiac surgery’. Reference lists
of recent review articles were also scanned for additional citations. The literature
search was further supplemented by abstracts from international cardiac surgery
congresses, which took place between January 2009 and July 2011. Review publi-
cations were excluded from the analysis. The search identiﬁed nine potential
publications of which eight focused speciﬁcally on the prophylaxis of SSI in cardiac
surgery. These studies concerned the use of two GCCI i.e. Collatamp (EUSA Pharma
[Europe], Oxford, United Kingdom) and GENTA-COLL resorb (RESORBA Wundver-
sorgung GmbH & Co. KG, Nuremberg, Germany). Collatamp contains gentamicin
sulphate at a rate of 2 mg/cm.2 The collagen in Collatamp is present at 2.8 mg/cm2
and is type I collagen from a renatured bovine or equine source. One Genta-Coll
collagen-gentamicin sponge of 2.5  2.5  0.5 cm contains 35 mg native equine
collagen ﬁbrils and 25 mg gentamicin sulphate, equivalent to 13.82e17.88 mg
gentamicin.
The outcomemeasures of primary interest were the rate of SSI, need for surgical
revision and re-hospitalisation as well as level of antibiotic usage. The level of
evidence for each study was graded according to the criteria developed by Car-
ruthers et al.16
3. Clinical experience
To date there have been nine clinical studies which have focused
on the local application of gentamicin-containing collagen implants
(GCCI) in the prophylaxis and treatment of SSI following cardiac
surgery (Table 1). Four of the studies were of randomised,
controlled design; four studies focused on a patient series with
historical or contemporary controls and one study included
a consecutive patient series without a control group. Three of the
studies were graded as level 1.16 In total these studies represent
experience in n ¼ 5026 patients treated prophylactically with GCCI
(n ¼ 4673 with Collatamp and n ¼ 353 with Genta-Coll) following
cardiac surgery. In 42 patients GCCI were used on a therapeutic
basis.
3.1. Prophylaxis
The ﬁrst randomised controlled study (and also the largest study
to date) focusing on the prophylactic use of GCCI following cardiac
surgery was published in 2005 (Table 1).17 The majority of the
subjects (73%) required a CABG via median sternotomy. At baseline
the mean age of patients was 68 years; 76 were male and 18% had
diabetes.
This large-scale study demonstrated a relative risk reduction
in SSI of 47% in the GCCI-treated patients compared to those who
received IV antibiotics alone. The incidence of sternal wound
infection was 4.3% in the GCCI group and 9.0% in the control
group (RR 0.47; 95% CI 0.33e0.0.68; p < 0.001). The use of GCCI
as adjunctive treatment also signiﬁcantly reduced the need for
surgical revision by 54% (2.3% vs 4.0%, p ¼ 0.03) and antibiotic
usage by 64% (11.6% vs 18.0%, p < 0.001). In a sub-set analysis theuse of GCCI was shown to be even more beneﬁcial in preventing
both superﬁcial and deep SSI in high-risk patients. In either
obese patients or in those with diabetes the relative risk of
developing deep SSI was reduced by 56% (2.4% vs 4.4%; RR 0.56;
95% CI 0.31e1.00; p ¼ 0.047) with use of GCCI in conjunction
with standard treatment. In a separate analysis the authors
demonstrated that the adjuvant use of GCCI with IV antibiotics
was cost saving. This was due to fewer wound infections and
lower costs despite the cost of the implants in all patients and
especially in high-risk patients e.g. those with diabetes or
BMI > 25 kg/m2.7
Early operation for bleeding was more common in the GCCI
group (4% vs 2.3%, p ¼ 0.03). The study authors suggested that the
incidence of early operation for bleeding in the GCCI group was
similar to that seen in routine practice, and that the re-operation
rate in the control group was lower than expected. There was no
signiﬁcant difference between the groups for all other general
outcome measures e.g. hospital mortality, post-operative renal
function etc. In a separate analysis of the microbiological ﬁndings
from this study23 the authors showed that GCCI reduced the inci-
dence of SSI caused by all major clinically important bacterial
species apart from Propionibacterium acnes. There was also no
indication of any increase in the occurrence of gentamicin-resistant
isolates.
In 2009 the same authors published the results of a consecutive
series of 1359 patients in which GCCI had been used as routine
clinical practice (Table 1).3 The baseline characteristics of the
patients were similar to those followed in the earlier study. The
results were compared with those from the control group in the
previous study. The analysis demonstrated similar beneﬁt of using
GCCI (þstandard treatment) in signiﬁcantly reducing the rate of SSI
(overall, deep and superﬁcial) and also need for surgical revision
compared to standard treatment alone. Furthermore by comparing
the microbiological results against those from the 2005 study the
authors were also able to show that there had been no change in
types of causative bacteria and no absolute increase in SSIs caused
by aminoglycoside resistant microbes over time.
Four further studies have been published which support the
positive results from the Friberg studies (Table 1).4,10,20,21 Schersten
and colleagues were motivated to study the use of GCCI after
detecting an increase in the rate of deep sternal wound infection
following cardiac surgery at their centre.10 In 2005 the SSI had risen
to 1.9% of cases compared to 1.0e1.3% between 2001 and 2004. The
authors attributed this to an increase in the number of high-risk
patients undergoing surgery and also an increase in the number
of emergency operations where the patients were not adequately
prepared for surgery. Following the addition of GCCI to their stan-
dard treatment protocol in a consecutive and unselected series of
1091 patients operated on in 2006 the rate of mediastinitis dropped
to 0.75% (95% CI 0.22e2.18; p < 0.05) compared to the rate in the
previous year.
A recently published randomised, controlled study which
compared GCCI (þIV antibiotics) to a control group in which the
surgeons inserted a collagen only implant (þIV antibiotics) also
supports the positive outcome of the previously mentioned anal-
yses (Table 1).4 The patient population was similar to that of the
Friberg studies (i.e. 74% male; 30% patients with diabetes and 53%
undergoing CABG). The incidence of deep sternal wound infections
was 3.52% in the control group compared to 0.56% in the GCCI
group (Adjusted odds ratio, 0.15; 95% CI, 0.02e0.69; p ¼ 0.014). The
numbers needed to treat (NNT) for all sternal wound infections and
deep sternal wound infections were 26 and 33, respectively. The
study did not demonstrate any signiﬁcant differences in any of the
secondary outcome measures (e.g. post-operative bleeding)
between the two groups.
Table 1
Overview of GCCI clinical publications in cardiac surgery.
Author & evidence
grading
Product Study design and
population











operations in the ascending
aorta
n ¼ 1950 total patients
Group I: n ¼ 983 gentamicin-collagen
implant þ IV isoxazolyl-penicillin
Group II: n ¼ 967 IV isoxazolyl-
penicillin alone (control)
Wound infection (<2 mths post-operatively):
Group I: 4.3% (42/983) vs Group II: 9.0%
(87/967)(RR 0.47; 95% CI 0.33e0.68; p < 0.001)
Early reoperation for bleeding: Group I:
2.3% (22/983) vs Group II: 4.0% (39/967)
(RR 1.74; 95% CI 1.04e2.91; p ¼ 0.021)
Antibiotic treatment: Group I: 11.6%
(114/983) vs Group II: 18.0% (174/967)






CABG surgery via a median
sternotomy, with cardiopulmonary
bypass
n ¼ 542 total patients
Group I: n ¼ 272 gentamicin-collagen
implant þ IV antibiotics
Group II: n ¼ 270 IV antibiotics
alone (control)
Wound infection (<3 mths post-operatively):








n ¼ 2026 total patients
Group I: n ¼ 1091 gentamicin-
collagen implant þ IV isoxazolyl-
penicillin
Group II: n ¼ 935 IV isoxazolyl-
penicillin alone (historical controls)
Wound infection (mediastinitis): Group I:
0.75% (8/1091) vs Group II: 1.9% (18/935)
(95% CI 0.22e2.18; p < 0.05)
Friberg (2009)3
Level 4




of the thoracic aorta operated
via full median sternotomy
n ¼ 2326 total patients
Group I: n ¼ 1359 gentamicin-
collagen implant þ IV isoxazolyl-
penicillin,
Group II: n ¼ 967 IV isoxazolyl-
penicillin alone (control)
Wound infection (<60 days post-operatively):
Group I: 3.7% (50/1359) vs Group II: 9.0%
(87/967) p < 0.001
Surgical revision: Group I: 1.8% (24/1359)
vs Group II: 3.9% (38/967)(p < 0.001)
Bennett-Guerrero
(2010)19 Level 1
Collatamp Randomised, controlled, single-
blind, multicentre study
Patients undergoing cardiac
surgery and at high-risk
for sternal wound infection
(diabetes, BMI > 30 or both)
n ¼ 1502 total patients (n ¼
1006 with diabetes [67%] and n ¼
1137 BMI > 30 [76%])
Group I: n ¼ 753 gentamicin-
collagen implant þ IV antibiotics
Group II: n ¼ 749 IV antibiotics
alone (control)
Wound infection (<90 days post-operatively):
Incidence of all types of wound infection e Group I: 8.4%
(63/753) vs Group II: 8.7% (65/749) (n.s.)
Incidence deep wound infection e Group I: 1.9%
(14/753) vs Group II: 2.5% (19/749) (n.s.)
Incidence superﬁcial wound infection e Group I:
6.5% (49/753) vs Group II: 6.1% (46/749) (n.s.)
Re-hospitalisation for sternal wound infection
(<90 days post-operatively): Group I: 3.1% (23/753) vs
Group II: 3.2% (24/749) (n.s.)
Cohen (2010)20
Level 4
Collatamp Patient case series
Patients undergoing cardiac
surgery via sternotomy
n ¼ 216 total patients
Group I: n ¼ 108 gentamicin-collagen
implant þ standard treatment
Group II: n ¼ 108 standard treatment
alone (control)
Wound infection: Group I: 0.0% vs Group II:
9.0% (p ¼ 0.0220).
Raja (2011)21
Level 4
Collatamp Patient case series
Patients undergoing cardiac
surgery via sternotomy
n ¼ 194 total patients
Group I: n ¼ 97 gentamicin-collagen
implant þ standard treatment
Group II: n ¼ 97 standard treatment
alone (control)
Wound infection: Incidence of superﬁcial
wound infection e Group I: 2.1% (2/97) vs
Group II: 6.2% (6/97) (p ¼ 0.01). Incidence
of deep wound infection e Group I: 2.1% (2/97)
vs Group II: 3.1% (3/97)(n.s).
Post-operative complications: Need for intra-
aortic balloon pump e Group I: 2.1% (2/97) vs
Group II: 5.2% (5/97) (p ¼ 0.04). Need for
haemoﬁltration e Group I: 3.1% (3/97) vs







n ¼ 720 total patients
Group I: n ¼ 353 gentamicin-collagen
implant þ IV antibiotics
Group II: n ¼ 367 collagen implant þ
IV antibiotics (control)
Wound infection (<30 days): Incidence of deep
wound infection e Group I: 0.56% (2/353) vs
Group II: 3.52% (13/367) (Adjusted odds ratio,
0.15; 95% CI, 0.02e0.69; p ¼ 0.014). Incidence
of superﬁcial wound infection e Group I: 1.98%
(7/353) vs Group II: 2.98% (11/367) (n.s). NNT e
all sternal wound infections and deep sternal








n ¼ 42 patients treated with
gentamicin-collagen implant
Drainage samples were clear of infection for
all 42 patients prior to removal and no re-infection
occurred within 6 months of surgical debridement
* Collatamp EG, Collatamp G Cronocol, Duracoll Implant, Garacol, Garacoll, Garacoll Implant, Garamacin Pads, Garamycin, Garamycin Schwamm, Gentacoll,
Gentacoll Implant, Gentalyn, Gentimplant, Sulmycin, Sulmycin Implant E Schwamm, Sulmycin Implant Schwamm.
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ORIGINAL RESEARCHThe analysis of two recently presented patient series also
demonstrates the positive impact of GCCI in conjunction with
standard antibiotic prophylaxis (Table 1).20,21 In a retrospective
review Cohen and colleagues compared a group of 108 patientswho had received GCCI plus standard treatment to a group of
matched contemporary controls on a 1:1 basis.20 Seventy six per
cent of patients in both groups underwent isolated coronary bypass
surgery and 22% had diabetes. There was a signiﬁcant difference in
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GCCI vs 9% standard treatment; p ¼ 0.022). In a similar study Raja
and colleagues compared the adjunctive use of GCCI in a series of 97
patients deemed at high risk of developing SSI to a group of
matched controls who received standard treatment alone
(Table 1).21 This study demonstrated a signiﬁcant beneﬁt of GCCI,
which reduced the rate of superﬁcial wound infection by 66%
compared to standard treatment alone (2.1% GCCI vs 6.2% standard
treatment; p ¼ 0.01). Although the patients in the GCCI group also
had a lower rate of deep wound infection compared to the control
group, this difference did not reach statistical signiﬁcance. Patients
in the GCCI group also had signiﬁcantly less requirement for intra-
aortic balloon pump and haemoﬁltration. No side effects attribut-
able to GCCI were reported.
In a study, which focused on a similar patient population but
speciﬁcally in patients undergoing CABG the rate of SSI was
numerically lower in the GCCI group (4.0%,11/272) compared to the
standard treatment group (5.9%, 16/270) (Table 1).18 However, this
difference did not reach statistical signiﬁcance. There were three
cases of mediastinitis (1.1%) in the GCCI group and ﬁve (1.9%) in the
control group (n.s.). Bennett-Guererro and colleagues also reported
equivocal results in 2010 in 1502 US patients at high-risk of
developing SSI (i.e. diabetes and or BMI > 30) (Table 1).19 No
signiﬁcant difference could be detected between the
GCCI þ standard treatment group and those patients receiving
standard treatment alone for any of the primary or secondary
outcomemeasures. For example the incidence of all types of wound
infection was 8.4% in the GCCI group vs 8.7% in the standard treat-
ment group (n.s.) and for deep wound infection the corresponding
ﬁgures were 1.9% and 2.5% respectively (n.s.). The re-hospitalisation
rate for sternal wound infection (<90 days post-operatively) was
3.1% in theGCCI group vs 3.2% in the standard treatment group (n.s.).
3.2. Treatment
The therapeutic use of GCCI has been studied in a series of 42
patients with deep sternal wounds following elective cardiac
surgery (Table 1).22 A third of patients were suffering from diabetes
and nearly half of the population were classiﬁed as obese. Patients
underwent radical wound debridement with sternal ﬁxation,
placement of retrosternal suction drainage and utilising bilateral
pectoralis major muscle ﬂaps. Two GCCI (10 cm  10 cm) were
placed underneath, above and between the sternal edges and
patients were also given IV antibiotics for up to 3 weeks. Suscep-
tibility testing revealed that 8 out of the 52 infections were caused
by organisms that were resistant to gentamicin. Eight of the 42
patients underwent prolonged ventilation and three out of 42 had
multiple organ failure following surgical debridement, which
complicated the post-operative course.
Out of 19 patients tested high gentamicin levels (>300 mg/mL)
were detected in themediastinal effusions for 36 h post-operatively,
whereas the plasma levels were below 2 mg/mL. Drainage samples
were clear of infection for all 42 patients prior to removal and no re-
infection occurred within 6 months of the surgical debridement. No
deaths occurred and no adverse events associated with GCCI were
detected.
4. Discussion
Themajority of the studies published to date have demonstrated
that prophylactic use of GCCI can signiﬁcantly reduce the wound
infection rate following cardiac surgery (via sternotomy) compared
to standard treatment alone. The adjunctive use of GCCI is partic-
ularly beneﬁcial in high-risk patients such as those with diabetes
and in obese patients. GCCI have also been shown to signiﬁcantlyimprove the morbidity associated with SSI following cardiac
surgery by shortening the recovery phase and length of hospital
stay; reducing the need for surgical revision and use of antibiotics.
As a result of reducing the SSI rate and subsequent complications
GCCI have been shown to be cost saving across a wide spectrum of
patients. GCCI may also have a therapeutic role to play in patients
with deep sternal wounds.
Of the eight ‘prophylactic’ studies reviewed two did not show
any signiﬁcant beneﬁt of local application of GCCI. In contrast to
the six positive publications in cardiac surgery the study by
Bennett-Guerrero and colleagues did not demonstrate any
beneﬁt of use of GCCI over standard treatment. The authors have
put forward a combination of factors that they think may go
some way to explaining the lack of beneﬁt seen in the GCCI group
including differences in design and ethnic differences between
this study and the other positive cardiac studies. One important
difference which the authors do not highlight is the fact that the
protocol for the Bennett-Guerrero study required that the
implants be wetted in saline prior to implantation.24 The effect of
the wetting of the implants has been researched by Lovering and
colleagues and they have shown that pre-soaking may impact on
the gentamicin release proﬁle of the GCCI to cause premature
depletion of the active compound in addition to that lost during
the pre-soaking period.25 The manufacturer’s recommendation is
that GCCI should be used dry prior to implantation.26 Friberg
points out that in contrast to the other published studies a large
proportion of the sternal wound infections in the Bennett-
Guerrero study were caused by gram-negative rods which are
not normally found on the skin on the chest (and should not be
present in the air in operating rooms) and this might suggest that
contamination may have occurred later in the post-operative
phase.27
Eklund et al. also showed no additional beneﬁt of GCCI in
reducing wound infection rate following cardiac surgery. The
authors themselves concluded that the study population might
have been too small to draw conclusions.185. Conclusion
This review demonstrates that when used dry prior to insertion
GCCI can be effective in reducing the rate of SSI following cardiac
surgery. GCCI have also been shown to be cost saving as they reduce
the substantial morbidity associated with deep SSI. The adjunctive
use of GCCI is particularly beneﬁcial in high-risk patients. GCCI may
also have a role to play in the treatment of deep sternal wound
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